Papillary Renal Cell Carcinoma

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

MET, MITF, PRCC, VHL, TFE3, KRT7, ERBB2, GSTP1, SLC2A1, ELOC, POMC, PIK3CA, ADIPOQ, RPL14, INPP4B, FPGT, TNFSF10, CRADD, UNC5C, TAGLN2, BAP1, KDM5C, PEBP1, MLLT10, PAK1, TSC1, TP53, TGM2, PDHB, HNF1B

MET, MITF, PRCC, VHL, TFE3, KRT7, ERBB2, GSTP1, SLC2A1, ELOC, POMC, PIK3CA, ADIPOQ, RPL14, INPP4B, FPGT, TNFSF10, CRADD, UNC5C, TAGLN2, BAP1, KDM5C, PEBP1, MLLT10, PAK1, TSC1, TP53, TGM2, PDHB, HNF1B, HNF1A, NF2, SOD2, SLC5A3, PGK1, ACY1, RYR1, RELA, PVALB, PTGS2, PTEN, ZNF536, ACHE, KEAP1, AHNAK, LMAN2L, CARD11, SLC49A4, NAV3, ZNF765, NLRP12, ZNF804A, CSMD3, LRRK2, ASB15, DNHD1, FAAH2, FLCN, OR4C13, VMO1, MSGN1, FAM111B, BIRC7, SPTBN4, CUL7, FMN2, NDRG1, CPQ, BTG3, AKAP13, RNF139, PDXDC1, SYNE2, PRAME, YIPF3, PNKD, SETD2, SHANK1, LRP1B, TET2, PBRM1, PIDD1, AP5M1, OGG1, SFRP2, APRT, MUC4, IL6, ALDH1A1, ALK, ALOX5, IFNA2, HSPD1, HSPB1, HSPA9, ALOX12B, ANXA4, APAF1, BIRC5, HARS1, EEF2, BCHE, GSTT1, GSTM1, GRB7, GJB1, EPAS1, MTOR, IL6R, IL4R, IL13, KRT32, CNN2, SCARB1, CASP2, CAPG, M6PR, ALAD, LDHB, L1CAM, CRABP1, KRT8, KCNMA1, DAPK1, CTSD, CTSB, CRYAB, FLT1, CDC73, HABP2, LMNA, FOXE1, MINPP1, VEGFA, AMACR, KDR, CD38, FH, MME, RASSF1, CA9, MYC, KIT, SNORD14D, SNORD14C, CD47, MIR1180, TWSG1, MIR1293, MIR379, KMT2C, ACE2, FBXO47, EIF2AK4, MIR34A, MIR200C, MIR181C, MIR134, MIR127, FBXO11, AKT1, DDR1, RAB37, APC, CDC34, SETDB2, BRAF, SNORD35B, RIOX2, BSG, BUB1, SNORD14E, SNORD14B, MEG3, DHCR24, LARP6, CDH1, HIF1A, TOP2A, TIMP3, TIMP1, UBE2K, SYP, IGFBP7, SLC16A1, SFPQ, RRM2, SNORD15A, CD82, PYCR1, PTK7, CFP, PAX2, MUC1, TBC1D25, OAT, NONO, NFE2L2, XRCC1, PAX8, FZD1, KDM4C, CDR2, CMA1, APH1A, CD274, CLDN7, MCTS1, MCAT, UBE2S, HAVCR1, ACE, CUL3, RALBP1, EGF, EGFR, ELAVL2, ETFA, NAPSA, FGFR2, FOLH1, GABPA, MIR3199-2

Drugs

(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate, 26 base single stranded phosphodiester DNA oligonucleotide, 4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline

(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate, 26 base single stranded phosphodiester DNA oligonucleotide, 4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline, Aldesleukin ( PROLEUKIN ), Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex ( ONCOPHAGE ), Autologous renal cell tumor vaccine, Axitinib ( INLYTA ), Bevacizumab ( Equidacent, AVASTIN, Aybintio, MVASI ), Everolimus ( AFINITOR, VOTUBIA ), Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM), Girentuximab ( RENCAREX ), HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMPMMPMUC-RGS), Human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and nonglycosylated) (inhalation use), Humanized anti-KSA monoclonal antibody-human interleukin-2 fusion protein, Interferon gamma 1b ( ACTIMMUNE, IMUKIN ), Iodine (131I) chimeric IgG monoclonal antibody cG250, N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate, Naptumomab estafenatox, Pazopanib hydrochloride ( VOTRIENT ), Recombinant human interleukin-21, Recombinant modified vaccinia Ankara expressing human 5T4, Siltuximab ( SYLVANT ), Sorafenib tosylate ( NEXAVAR ), Sunitinib malate ( SUTENT ), Talactoferrinum alfa, Temsirolimus ( TORISEL )

Interested in hearing about new therapies?

Papillary renal cell carcinoma is a rare subtype of renal cell carcinoma, arising from the renal tubular epithelium and showing a papillary growth pattern, which typically manifests with hematuria, flank pain, palpable abdominal mass or nonspecific symptoms, such as fatigue, weight loss or fever. Symptoms related to metastatic spread, such as bone pain or persistent cough, are frequently associated since early diagnosis is not common. It is typically multifocal, bilateral, and in most cases sporadic, although different hereditary syndromes, such as Hereditary leiomyoma renal cell carcinoma, Birt-Hogg-Dubé syndrome and Tuberous sclerosis, may predispose to the development of papillary renal cell carcinoma.